Erutic – 50 (Erlotinib)

Introduction to Tarceva (Erlotinib) 50mg 

Tarceva (Erlotinib) 50mg is a targeted anticancer medicine used in the treatment of certain types of lung cancer and pancreatic cancer. It works by blocking specific growth signals that cancer cells need to grow and multiply.

Tarceva 50mg is classified under Prescription Medicines, Oncology Medicines, Targeted Cancer Therapies, and Tyrosine Kinase Inhibitors (TKIs). It contains Erlotinib, which helps slow or stop the growth of cancer cells.

In some markets, Erutic – 50 50mg is available as a local brand containing the same active ingredient Erlotinib, offering similar therapeutic effects when prescribed by a qualified healthcare professional.

What Is Tarceva (Erlotinib)? 

Tarceva is the brand name for Erlotinib, an oral medication widely used in targeted cancer therapy.

Erlotinib belongs to a class of medicines known as Epidermal Growth Factor Receptor (EGFR) inhibitors, a type of tyrosine kinase inhibitor. These medicines block signals responsible for cancer cell growth.

Generic versions such as Erutic – 50 50mg contain the same active compound and may be used depending on physician recommendation and availability.

Drug Class and Mechanism of Action 

Erlotinib is classified as an EGFR tyrosine kinase inhibitor with antineoplastic properties.

How Erlotinib Works 

It works in several ways:

• Blocks EGFR signaling pathways
• Inhibits cancer cell proliferation
• Promotes cancer cell death

How Tarceva Works in the Body 

Certain cancers depend on EGFR signals for growth and survival.

Key Actions of Erlotinib 

• Slowing tumor growth
• Reducing cancer cell division
• Improving targeted therapy outcomes

Generic versions such as Erutic – 50 provide similar anticancer effects when used correctly.

Medical Uses of Tarceva 50mg 

For Non-Small Cell Lung Cancer 

Erlotinib is commonly used in patients with EGFR mutation-positive non-small cell lung cancer.

Potential Benefits 

• Targeted cancer treatment
• Improved progression-free survival
• Better tolerability compared to some chemotherapy

For Pancreatic Cancer 

It may be used alongside other treatments in pancreatic cancer.

Treatment Benefits 

• Slowed disease progression
• Improved treatment response
• Enhanced disease control

Who Can Take Erutic – 50 50mg? 

Eligibility Criteria 

Patients may be prescribed this medicine if they:

• Have lung or pancreatic cancer
• Are suitable for targeted therapy
• Are evaluated by an oncologist

Who Should Avoid Tarceva 50mg 

This medicine should NOT be used by:

• Patients with severe liver disease
• Individuals with hypersensitivity to Erlotinib
• Pregnant or breastfeeding women unless advised

Tarceva 50mg Dosage and Administration 

Standard Dosage Guidelines 

• Typical dose: 50mg once daily (as adjusted by doctor)
• Taken on an empty stomach
• Swallow tablet whole with water

Dosage Adjustments 

Doctors may adjust dosage depending on:

• Side effects
• Liver function
• Treatment response

Side Effects of Tarceva 50mg 

Common Side Effects 

• Skin rash
• Diarrhea
• Fatigue
• Loss of appetite

Serious Side Effects 

• Lung problems (interstitial lung disease)
• Liver toxicity
• Severe skin reactions
• Eye disorders

Storage 

Store below 30°C in a dry place, away from moisture and light. Keep out of reach of children.

Frequently Asked Questions (FAQs) 

1. Is Erlotinib chemotherapy? 

No, it is a targeted cancer therapy.

2. Should it be taken with food? 

No, it should be taken on an empty stomach.

3. Can it cause skin problems? 

Yes, rash is a common side effect.

4. Is it used long-term? 

Yes, depending on patient response.

5. Is Erutic – 50 the same as Tarceva? 

Yes, both contain Erlotinib with similar effects.

6. Do I need a prescription? 

Yes, it is a prescription-only anticancer medicine.

Medical Disclaimer 

Disclaimer:
This content is for informational purposes only and should not be considered medical advice. Always consult a qualified healthcare professional before starting cancer treatment.